Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of proton therapy on cognition in adults with brain tumors: a systematic review.

Journal of neuro-oncology·2025

Same author

Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors.

Multiple sclerosis and related disorders·2023

Same author

Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection.

British journal of haematology·2023

Same author

Superomedial pedicle skin-reducing mastectomy in ptotic and large-sized breasts with two-stage reconstruction through transaxillary video-assisted technique: An effective surgical and anesthetic approach.

Frontiers in surgery·2023

Same author

Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series.

Journal of endocrinological investigation·2019

Same author

Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.

Leukemia·2019

Same journal

Deconvoluting MLL1-dependent pathways in hematopoiesis and leukemogenesis.

Leukemia supplements·2016

Same journal

New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance.

Leukemia supplements·2016

Same journal

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

Leukemia supplements·2016

Same journal

Dissecting reprogramming, differentiation and conversion with network biology.

Leukemia supplements·2016

Same journal

Insights into the pathophysiology and therapy of myeloproliferative neoplasms from mouse models.

Leukemia supplements·2016

Same journal

Myeloid differentiation and the leukemia-initiating cell.

Leukemia supplements·2016

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Prognostic markers in AML: focus on CBFL.

R Cairoli¹, A Beghini², M Turrini³

¹Department of Internal Medicine, Hematology Section, Valduce Hospital, Como, Italy; Division of Haematology, Niguarda Hospital, Milan, Italy.

Leukemia Supplements

|May 14, 2016

Summary

This summary is machine-generated.

Prognostic risk in acute myeloid leukemia (AML) is determined by clinical factors like age and genetic markers. Understanding these variables aids in personalized treatment decisions for AML patients.

Keywords:

AML CBFL KIT cytogenetic mutations prognostic factors

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Experiment Videos

Last Updated: Mar 21, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Area of Science:

Hematology
Oncology
Genetics

Background:

Acute myeloid leukemia (AML) is a complex blood cancer with increasing incidence in aging populations.
Accurate prognostic assessment is crucial for guiding intensive treatment decisions, including induction therapy, intensification, and allogeneic stem cell transplantation.
Risk stratification helps personalize patient management in clinical practice.

Purpose of the Study:

To identify key clinical, cytogenetic, and molecular variables for assessing prognosis in non-acute promyelocytic AML.
To focus on prognostic factors specifically relevant to core binding factor leukemia, a subtype of AML.
To provide guidance for clinicians counseling individual AML patients regarding their risk.

Main Methods:

Review of clinical variables including age, performance status, and tumor burden.
Analysis of cytogenetic and gene mutation data.
Examination of prognostic indicators in non-acute promyelocytic AML, with a focus on core binding factor leukemia.

Main Results:

Clinical variables such as age, performance status, and tumor burden are important prognostic indicators.
Cytogenetic and gene mutation analyses provide critical genetic information for risk assessment.
These factors collectively contribute to defining the prognostic risk for individual AML patients.

Conclusions:

A combination of clinical and genetic variables is essential for accurate AML prognosis.
Prognostic assessment is vital for tailoring treatment strategies in AML.
Understanding these factors improves patient counseling and therapeutic decision-making for AML.